Given the critical role of EGFR in cancer, it has become a significant target for targeted therapies. There are two main types of EGFR inhibitors: tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. TKIs, such as gefitinib and erlotinib, bind to the intracellular tyrosine kinase domain of EGFR, preventing its activation. Monoclonal antibodies, such as cetuximab and panitumumab, target the extracellular domain of the receptor, blocking ligand binding and subsequent receptor dimerization.
